Permanent cessation of menses after 12 months of amenorrhea due to loss of ovarian follicular activity.
Also known as: menopause, perimenopause, climacteric, vasomotor symptoms, hot flashes
Overview
Permanent cessation of menstruation diagnosed retrospectively after 12 consecutive months of amenorrhea in the absence of other pathology. Average age 51 in the US. Perimenopause is the menopausal transition characterized by cycle irregularity and vasomotor symptoms preceding the final menstrual period; ovulation still occurs intermittently despite elevated FSH, so contraception is continued until 12 months of amenorrhea after age 50 (24 months if younger than 50).
Epidemiology
Universal in women who reach reproductive senescence. Vasomotor symptoms affect ~75-80% of women; ~25% have severe symptoms lasting >5 years (median duration ~7-10 years).
Try two board-style Menopause questions
Real questions from the FirstPassPA bank, with the full explanation. Pick an answer — no signup, no email.
Question 1ReproductiveMedium
A 52-year-old woman presents with daily hot flashes, night sweats, and difficulty sleeping that have persisted for the past year and are interfering with her work. She also reports vaginal dryness and pain with intercourse. Her last menstrual period was 18 months ago. She has no personal or family history of breast cancer, venous thromboembolism, or coronary artery disease, and she has not had a hysterectomy. Her blood pressure and BMI are normal. After counseling, she elects to start systemic menopausal hormone therapy, and she and her clinician prioritize the safest effective regimen. Which of the following hormone regimens is most appropriate for this patient?
ATransdermal estradiol plus micronized progesterone
BTransdermal estradiol plus medroxyprogesterone acetate
CConjugated estrogen plus medroxyprogesterone acetate
DTransdermal estradiol plus vaginal estradiol
EOral estradiol plus micronized progesterone
Reveal answer & full explanation
Correct answer: A — Transdermal estradiol plus micronized progesterone
ATransdermal estradiol plus micronized progesterone✓
BTransdermal estradiol plus medroxyprogesterone acetate
CConjugated estrogen plus medroxyprogesterone acetate
DTransdermal estradiol plus vaginal estradiol
EOral estradiol plus micronized progesterone
Why Transdermal estradiol plus micronized progesterone is correct
Amenorrhea for 18 months with disabling vasomotor symptoms (hot flashes, night sweats, sleep disruption) plus genitourinary symptoms establishes symptomatic menopause warranting systemic hormone therapy
She has an intact uterus, so systemic estrogen must be combined with a progestogen for endometrial protection; this regimen provides a complete combined estrogen-progestogen course
Transdermal estradiol bypasses hepatic first-pass metabolism and carries lower venous thromboembolism and stroke risk than oral estrogen, and micronized progesterone has a more favorable breast and metabolic profile than medroxyprogesterone acetate (NAMS/Menopause Society 2022)
When the explicit goal is the safest effective systemic therapy in an average-risk woman, the transdermal estradiol plus micronized progesterone regimen is the guideline-preferred single best choice
Why the others are wrong
Conjugated estrogen plus medroxyprogesterone acetate — a complete and guideline-valid combined regimen, but oral conjugated estrogen carries higher VTE/stroke risk and MPA has a less favorable breast/metabolic profile, so it is not the safest option for this average-risk patient (right-concept-higher-risk)
Transdermal estradiol plus medroxyprogesterone acetate — the estrogen route is the preferred one, but medroxyprogesterone acetate carries a less favorable breast and metabolic profile than micronized progesterone, so the pairing is not the safest effective regimen (right-route-wrong-progestogen)
Oral estradiol plus micronized progesterone — the progestogen is the preferred one, but oral estradiol undergoes hepatic first-pass metabolism and raises VTE and stroke risk relative to transdermal delivery (right-progestogen-wrong-route)
Transdermal estradiol plus vaginal estradiol — appeals because the transdermal route is the lower-risk one and vaginal estrogen targets her dryness and dyspareunia, but the regimen contains no progestogen, and systemic estrogen in a woman with an intact uterus must be paired with a progestogen to prevent endometrial hyperplasia and cancer (right-route-no-endometrial-protection)
Transdermal estradiol carries lower VTE/stroke risk than oral estrogen and is preferred when minimizing thrombotic risk
Use the lowest effective dose for symptom control
Question 2ReproductiveEasy
A 55-year-old woman has had absent menses for 14 months following 2 years of irregular cycles. She reports 8 to 10 hot flashes daily and severe night sweats that disrupt her sleep, along with vaginal dryness and dyspareunia. She has an intact uterus and no history of breast cancer, cardiovascular disease, or venous thromboembolism. Her mammogram, Pap smear, and bone density are normal. Which of the following is the most appropriate initial treatment for her vasomotor symptoms?
ALow-dose oral paroxetine daily
BOral gabapentin taken at bedtime
COral conjugated estrogen monotherapy
DVaginal estradiol cream nightly
EEstradiol patch plus micronized progesterone
Reveal answer & full explanation
Correct answer: E — Estradiol patch plus micronized progesterone
ALow-dose oral paroxetine daily
BOral gabapentin taken at bedtime
COral conjugated estrogen monotherapy
DVaginal estradiol cream nightly
EEstradiol patch plus micronized progesterone✓
Why estradiol patch plus micronized progesterone is correct
This early-postmenopausal woman has moderate-to-severe vasomotor symptoms (frequent hot flashes and disruptive night sweats) plus genitourinary symptoms, and she has no contraindications to systemic hormone therapy.
Menopausal hormone therapy (MHT) with estrogen is the most effective treatment for vasomotor symptoms.
Because she has an intact uterus she must also receive a progestogen to protect the endometrium from estrogen-driven hyperplasia and carcinoma.
Transdermal estradiol avoids hepatic first-pass metabolism and carries lower VTE and stroke risk than oral estrogen.
Micronized progesterone is the preferred progestogen given its more favorable breast and metabolic profile.
She falls within the window of starting MHT before age 60 and within 10 years of menopause, where benefits outweigh risks.
Why the others are wrong
Low-dose oral paroxetine daily — a non-hormonal SSRI option that only modestly reduces hot flashes and is reserved for women who cannot or prefer not to take hormones; right-concept-wrong-setting since she has no contraindication to estrogen.
Vaginal estradiol cream nightly — treats her vaginal dryness and dyspareunia but delivers minimal systemic estrogen, so it will not relieve hot flashes or night sweats (confused-with genitourinary-only therapy).
Oral gabapentin taken at bedtime — can blunt nighttime hot flashes and is another non-hormonal alternative, but it is less effective than systemic estrogen and causes sedation and dizziness (anchoring on the sleep disruption).
Oral conjugated estrogen monotherapy — systemic estrogen is the most effective treatment for her hot flashes and night sweats, but with an intact uterus unopposed estrogen drives endometrial hyperplasia and carcinoma, so a progestogen must be added, and oral estrogen also carries higher VTE and stroke risk than transdermal estradiol (confused-with therapy for a woman after hysterectomy).
Additional high-yield points
Systemic estrogen also treats genitourinary symptoms, so a separate vaginal preparation is often unnecessary when MHT is started.
Non-hormonal agents (SSRIs/SNRIs, gabapentin, oxybutynin, fezolinetant) are first-line only when hormone therapy is contraindicated or declined.
Unopposed estrogen in a woman with an intact uterus raises the risk of endometrial hyperplasia and carcinoma — always pair with a progestogen.
That's 2. Get 7,700+ more.
Unlock the full FirstPassPA bank: 7,700+ board-style questions, flashcards, and an AI tutor that explains every answer. Your 7-day free trial includes everything, and there's no credit card required.
You've read your 2 free diagnosis previews. Create your free account to unlock the full Menopause outline — plus all 514 diagnoses, 7,700+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.
Progressive depletion of ovarian follicles → decreased inhibin B and AMH → loss of negative feedback → elevated FSH (and LH). Reduced estradiol production produces vasomotor symptoms (hypothalamic thermoregulatory instability), genitourinary atrophy, bone loss, and adverse lipid/metabolic changes.
Anxiety/panic disorder — Hot flushes with anxiety; psychiatric history
Diagnostic workup
Labs
Diagnosis is clinical for women >45 with typical symptoms — labs not required
FSH (≥25-30 IU/L, repeated) — useful in younger women or atypical presentations
TSH, prolactin, hCG to exclude alternatives
Estradiol typically low but variable in perimenopause
Lipid panel, bone density (DEXA) — baseline screening per USPSTF 2025 (age ≥65; younger postmenopausal women when risk factors prompt a clinical risk tool that shows increased risk)
Imaging
Endometrial evaluation (TVUS, biopsy) for any postmenopausal bleeding
Vaginal moisturizers and lubricants for genitourinary symptoms
Topical vaginal estrogen — estradiol cream, ring, or tablets — first-line for isolated GSM, minimal systemic absorption
Systemic hormone therapy for moderate-to-severe vasomotor symptoms (see by_subtype)
Systemic hormone therapy (HT)
Estrogen alone (transdermal estradiol patch, oral conjugated equine estrogen, oral estradiol) — for women without a uterus
Estrogen + progestin (combined oral, sequential or continuous; or estrogen + levonorgestrel IUD) — for women with a uterus to protect endometrium
Individualize dose, route, and duration (appropriate, often lowest effective dose) with periodic reassessment; no arbitrary stop at a fixed age such as 65
Initiate ideally <60 yo and within 10 years of menopause ('timing hypothesis')
Contraindications: history of breast cancer or other estrogen-dependent cancer (including high-risk endometrial cancer), unexplained vaginal bleeding, prior or active VTE, stroke/TIA, MI or coronary heart disease, known thrombophilia, active liver disease
Transdermal estradiol bypasses hepatic first-pass metabolism and is associated with lower VTE and stroke risk than oral estrogen (preferred when VTE risk is a concern); micronized progesterone is generally preferred over medroxyprogesterone acetate (observational data suggest a more favorable breast and VTE profile)
Nonhormonal options for vasomotor symptoms
SSRIs/SNRIs — paroxetine (FDA-approved for VMS, avoid with tamoxifen), venlafaxine, escitalopram
Gabapentin (especially night sweats)
Oxybutynin (clonidine is no longer recommended by NAMS 2023: modest benefit, frequent adverse effects)
Fezolinetant — neurokinin-3 receptor antagonist; boxed warning for hepatotoxicity, so check liver tests at baseline and during treatment. Elinzanetant (dual NK-1/NK-3 antagonist, FDA-approved 2025) is a newer option
Any postmenopausal bleeding requires evaluation for endometrial cancer (endometrial biopsy or TVUS, with biopsy if thickness >4 mm).
Women with an intact uterus on systemic estrogen MUST also receive progestin to prevent endometrial hyperplasia/cancer.
Vaginal estrogen is safe even in women with prior estrogen-receptor-positive breast cancer in many cases (with oncology consultation); minimal systemic absorption.
Hormone therapy initiated <60 yo and within 10 years of menopause has the most favorable risk-benefit profile (WHI re-analyses).
Paroxetine inhibits CYP2D6 and decreases tamoxifen efficacy — avoid in patients taking tamoxifen; use venlafaxine instead.
Combined estrogen-progestin therapy raises breast cancer risk (WHI: about 8 extra cases per 10,000 women per year, rising with duration) plus VTE and stroke; estrogen-alone after hysterectomy did not increase breast cancer in WHI, so the progestogen accounts for most of the excess. HT is not used to prevent chronic disease (USPSTF grade D).
References
NAMS 2022 — The 2022 Hormone Therapy Position Statement of the North American Menopause Society (Menopause 2022)
ACOG PB 141 — ACOG Practice Bulletin No. 141: Management of Menopausal Symptoms
USPSTF 2022 — Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Persons: USPSTF Recommendation Statement (JAMA 2022)
NAMS 2023 — The 2023 Nonhormone Therapy Position Statement of The North American Menopause Society (Menopause 2023;30(6):573-590)
Practice Reproductive questions on FirstPassPA
Turn this outline into retention. 7,700+ board-style questions with an AI tutor that explains every answer — free to start, no card required.
Educational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA or PAEA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants; End of Rotation™ is a program of the Physician Assistant Education Association.